PolyPid Ltd. (NASDAQ:PYPD) Shares Purchased by Rosalind Advisors Inc.

Rosalind Advisors Inc. lifted its holdings in PolyPid Ltd. (NASDAQ:PYPD) by 50.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,022,521 shares of the company’s stock after acquiring an additional 343,353 shares during the period. PolyPid makes up 1.6% of Rosalind Advisors Inc.’s portfolio, making the stock its 19th biggest position. Rosalind Advisors Inc. owned about 0.10% of PolyPid worth $3,108,000 as of its most recent SEC filing.

Separately, Stonepine Capital Management LLC purchased a new stake in PolyPid during the 3rd quarter worth $476,000. 26.47% of the stock is currently owned by institutional investors.

PolyPid Stock Performance

NASDAQ:PYPD opened at $2.81 on Friday. The firm has a 50-day moving average of $3.00 and a two-hundred day moving average of $3.21. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. The stock has a market cap of $28.64 million, a P/E ratio of -0.57 and a beta of 1.27. PolyPid Ltd. has a 1-year low of $2.37 and a 1-year high of $5.50.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). On average, research analysts expect that PolyPid Ltd. will post -1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. HC Wainwright reduced their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, December 26th. Rodman & Renshaw initiated coverage on PolyPid in a research report on Tuesday, January 28th. They set a “buy” rating and a $13.00 price target on the stock. Finally, RODMAN&RENSHAW raised shares of PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th.

PolyPid Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.